Impacto da hepatite C sobre o consumo de recursos e custos de pacientescom cirrose hepática no SUS / Impact of hepatitis C on resource use and costs of patients with liver cirrhosis in the Brazilian public healthcare system (SUS)

Objetivo: Avaliar o consumo de recursos relacionado ao tratamento de pacientes cirróticos com o vírus da Hepatite C (HCV) genótipo 1 (G1) e compará-lo ao de pacientes com cirrose não relacionada ao HCV no SUS. Métodos: Foram levantadas no banco de dados do DataSUS as hospitalizações por CID de cirrose entre 2008 e 2012. Dentre estas hospitalizações, foram levantados os pacientes com histórico de tratamento com interferon peguilado, no mesmo período, para identificar pacientescom HCV G1 prévia, como definido pelo Protocolo Clínico e Diretrizes Terapêuticas (PCDT) do SUS. As coortes de pacientes com ou sem HCV prévio (CH+HCV e CH-HCV) foram acompanhadas por 60 meses e comparadas em termos de uso de recursos. Para a avaliação econômica, custos unitários de medicamentos foram analisados a partir do Portal de Compras Governamentais e, para valoração de hospitalizações, a partir do DataSUS. Resultados: Gastos com hospitalização de pacientes cirróticossomaram aproximadamente R$ 108 milhões em 2012, podendo ser observado um aumento de 75% no gasto comparado a 2008. A maioria dos pacientes internados por CH com ou sem HCV estava entre as idades de 45 e 64 anos, sendo a média de idade de 52 anos, e grande parte do gênero masculino. Os gastos médios com hospitalizações por paciente foram de R$ 6.583,00 nos pacientes do grupo CH+HCV versus R$ 3.496,00 nos pacientes do grupo CH-HCV (p < 0,001). Aproximadamente 5% dos pacientes CH-HCV receberam transplante hepático comparado com 7% dospacientes CH+HCV. O custo relacionado ao transplante na população CH+HCV representou 78% do custo total contra 67% dos pacientes CH-HCV, sendo o custo médio atribuído a transplantes nos pacientes CH+HCV 17% superior à população sem HCV. Conclusão: Os custos hospitalares entre os pacientes cirróticos relacionados ou não ao HCV apresentaram uma distribuição diferente entre si e significativa para a perspectiva do SUS.

Objective: Evaluate resource consumption related to the treatment of cirrhotic patients with hepatitis C virus (HCV) genotype 1 (G1) and compare to patients with cirrhosis not related to HCV in the Brazilian public healthcare system (SUS). Methods: Hospitalizations for the diagnosis of cirrhosis were obtained from DatasSUS between 2008 and 2012. Among these hospitalizations, patients with a history of treatment with pegylated interferon in the same period were evaluated, to identify patients with previous HCV G1, as defined by the Clinical Protocol and Therapeutic Guideline (PCDT)from SUS. The cohorts of patients with or without previous HCV (CH+HCV and CH-HCV) were followed for 60 months and compared in terms of resource use. For the economic evaluation, unit costs of medications were analyzed based on the Government Procurement Portal and costs of hospitalization from DataSUS. Results: Hospitalization expenditures of cirrhotic patients totaled approximately R$108 million in 2012, with an increase of 75% in spending compared to 2008. Most patients admitted for CH with or without HCV were between the ages of 45 and 64 years, with a mean age of 52 years and were mostly male. Approximately 5% of patients CH-HCV received liver transplantation compared to 7% of patients CH+HCV. Costs related to transplantation in the CH+HCV populationaccounted for 78% of the total cost compared to 67% among CH-HCV patients, being the average transplantation cost 17% higher in patients CH+HCV when compared to the population without HCV. Conclusion: Hospitalization costs among cirrhotic patients with or without prior treatment of HCV showed a different distribution and differences were significant for the SUS perspective.

Tratamento inicial do choque por hemorragia controlada: avaliação tardia do efeito sinérgico de pentoxifilina e solução salina hipertônica / Hemodynamic and inflammatory response to volume replacement with crystalloid or hypertonic saline with and without pentoxifylline on experimental hemorrhagic shock

O trauma grave está associado a complexas alterações hemodinâmicas e microcirculatórias. A hipovolemia resultante da perda sanguínea e a inflamação desencadeada pelo trauma tecidual, além da própria isquemia tecidual sistêmica, são os principais fatores que levam a estas alterações. A solução salina hipertônica hiperoncótica (HSD) e a pentoxifilina vem sendo propostas como opções na ressuscitação volêmica do choque hemorrágico, mostrando efeito de modulação da resposta inflamatória e eficácia na restauração dos parâmetros hemodinâmicos. Objetivos: Avaliar a evolução dos mediadores inflamatórios e do burst oxidativo durante 4 horas, após reposição volêmica inicial no tratamento do choque hemorrágico controlado, com três diferentes tipos de solução: Ringer lactato, solução hipertônica hiperoncótica (HSD) e solução hipertônica hiperoncótica associada a pentoxifilina (PTX). Métodos: Anestesiamos e instrumentamos 20 porcos da raça Landrace de 28-32 kg. 5 animais foram randomizados para grupo Sham (apenas anestesiados e monitorizados) e outros 15 submetidos a choque hemorrágico controlado, com pressão arterial média (PAM) mantida em 40 mmHg por 30 minutos. Após o choque 5 animais foram tratados com 32 ml/kg de ringer lactato (grupo RL), 5 animais com 4 ml/kg de HSD (grupo HSD) e 5 animais com 4 ml/kg de HSD + 25 mg/kg de pentoxifilina. Além de medidas hemodinâmicas sistemicas e regionais, procedemos a determinação do burst oxidativo dos neutrófilos circulantes e dos mediadores inflamatórios (TNF alfa, interleucina 1, interleucina 6 e interleucina 10). Resultados: Os animais dos grupos HSD e PTX apresentaram diminuição significativa do burst oxidativo após a reposição volêmica, ao contrário do grupo RL, que apresentou comportamento contrário (p<0,001 para HSD versus RL e PTX versus RL após tratamento). TNF alfa e interleucinas também apresentaram valores estáveis nos grupos tratados com HSD e PTX...

Major trauma is associated with complex hemodynamic and microcirculatory changes. Volume depletion resulting from blood loss and inflammation triggered by tissue trauma, besides the systemic tissue ischemia, are the main factors leading to these changes. Hypertonic saline hyperoncotic (HSD) and pentoxifylline has been proposed as options in the resuscitation of hemorrhagic shock, showing the effect of modulation of the inflammatory response and efficacy in the restoration of hemodynamic parameters. Objectives: To evaluate the progression of inflammatory mediators and oxidative burst during 4 hours after initial resuscitation in the treatment of hemorrhagic shock, with three different solutions: Ringer lactate, hypertonic hyperoncotic solution (HSD) and hypertonic hyperoncotic solution associated with pentoxifylline (PTX). Methods: anesthetized and instrumented 20 Landrace pigs of 28-32 kg 5 animals were randomized to Sham group (only anesthetized and monitored) and 15 submitted to hemorrhagic shock. The mean arterial pressure (MAP) was maintained at 40 mmHg by 30 minutes. After shock 5 animals were treated with 32 ml / kg Ringer's lactate (RL group), 5 animals with 4 ml / kg HSD (HSD group) and 5 animals with 4 ml / kg of HSD + 25 mg / kg pentoxifylline. In addition to systemic and regional hemodynamic parameters, we determine the oxidative burst of circulating neutrophils and inflammatory mediators (TNF-alpha, interleukin 1, interleukin 6 and interleukin 10). Results: The animals in the HSD and PTX groups showed a significant decrease in oxidative burst after resuscitation, unlike the RL group, which showed an opposite (p<0.001 for HSD versus RL and RL PTX versus after treatment). TNF alpha and interleukins also showed stable values in the groups treated with HSD and PTX, whereas in animals treated with RL was significant increase of these mediators. The HSD was ineffective in normalizing some regional and systemic hemodynamic variables...

Epidemiological and microbiological analysis of ventilator-associated pneumonia patients in a public teaching hospital

Ventilator-associated pneumonia (VAP) is the most commonly-acquired infection in patients in intensive care units. We analyzed epidemiological and microbiological characteristics and the outcome, in a cohort of critically-ill patients with confirmed diagnosis of VAP. All patients who had been on mechanical ventilation (MV) for more than 48 hours were included in our study; material collection for microbiological analysis was done within the first 24 hours after beginning treatment or after changing antibiotics. There were 55/265 (20.7 percent) VAP cases diagnosed, at a rate of 21.6 episodes per 1,000 days of mechanical ventilation. Mean age of the patients was 66 years, with a mean APACHE II score of 26.7 + 7.0; male patients were more prevalent. The mortality rates in the intensive care unit (ICU) and during the hospital stay were 71 percent and 80 percent, respectively. MV duration in patients with VAP was 17 (range 3-43) days and among patients who had not developed VAP, 6 (2-32) days (p < 0.0001). 98.2 percent of the samples were positive, with a high prevalence of Gram-negative bacteria, mainly Acinetobacter calcoaceticus. Risk factors for death included age, MV duration and surgery. VAP incidence in this sample of critically-ill patients was high, with a high mortality rate. Control and prevention strategies based on continuing education of healthcare workers, developed by a multidisciplinary team, should be encouraged to minimize morbimortality of this infection.